You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
Safety, pharmacokinetics, and pharmacodynamics of CT-388, a signal-biased dual GLP-1/GIP receptor agonist, over 24 weeks in adults with obesity
Request medical material
Would you like to receive this poster via email to view later?